Affordable Access

Access to the full text

Targeted and Nontargeted α-Particle Therapies

Authors
  • McDevitt, Michael R.
  • Sgouros, George
  • Sofou, Stavroula
Type
Published Article
Journal
Annual Review of Biomedical Engineering
Publisher
Annual Reviews
Publication Date
Jun 04, 2018
Volume
20
Pages
73–93
Identifiers
DOI: 10.1146/annurev-bioeng-062117-120931
Source
Annual Reviews
Keywords
License
Yellow

Abstract

α-Particle irradiation of cancerous tissue is increasingly recognized as a potent therapeutic option. We briefly review the physics, radiobiology, and dosimetry of α-particle emitters, as well as the distinguishing features that make them unique for radiopharmaceutical therapy. We also review the emerging clinical role of α-particle therapy in managing cancer and recent studies on in vitro and preclinical α-particle therapy delivered by antibodies, other small molecules, and nanometer-sized particles. In addition to their unique radiopharmaceutical characteristics, the increased availability and improved radiochemistry of α-particle radionuclides have contributed to the growing recent interest in α-particle radiotherapy. Targeted therapy strategies have presented novel possibilities for the use of α-particles in the treatment of cancer. Clinical experience has already demonstrated the safe and effective use of α-particle emitters as potent tumor-selective drugs for the treatment of leukemia and metastatic disease.

Report this publication

Statistics

Seen <100 times